Phase II Trial of Ribociclib Plus Letrozole in Women With Recurrent Low-Grade Serous Carcinoma of the Ovary, Fallopian Tube, or Peritoneum: A GOG Partners Trial (GOG 3026).

Journal:: Journal of Clinical Oncology
Published:: 2025-12-13
DOI:: 10.1200/jco-25-01348
Affiliations:: 25
Authors:: 33

Go to article

Institutions	Authors	Share
OSU Comprehensive Cancer Center-Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC-James), United States of America (USA)	3.000000	0.09
The University of Texas Southwestern Medical Center (UT Southwestern Medical Center), United States of America (USA)	2.000000	0.06
Mount Sinai Medical Center (MSMC), United States of America (USA)	2.000000	0.06
Mayo Clinic, United States of America (USA)	2.000000	0.06
H. Lee Moffitt Cancer Center & Research Institute, United States of America (USA)	2.000000	0.06
The University of Texas MD Anderson Cancer Center, United States of America (USA)	2.000000	0.06
University of California, San Francisco (UCSF), United States of America (USA)	2.000000	0.06
UF Health Cancer Center, United States of America (USA)	2.000000	0.06
Endeavor Health, United States of America (USA)	2.000000	0.06
Saint Joseph Mercy Hospital, United States of America (USA)	1.000000	0.03
UNM Comprehensive Cancer Center, United States of America (USA)	1.000000	0.03
Roswell Park Cancer Institute (RPCI), United States of America (USA)	1.000000	0.03
Northside Hospital, United States of America (USA)	1.000000	0.03
Texas Oncology, United States of America (USA)	1.000000	0.03
OU Health Sciences Center (OUHSC), United States of America (USA)	1.000000	0.03
Ascension St. Vincent Hospital - Indianapolis, United States of America (USA)	1.000000	0.03
Houston Methodist Sugar Land Hospital, United States of America (USA)	1.000000	0.03
Premier Health Miami Valley Hospital South, United States of America (USA)	1.000000	0.03
NewYork-Presbyterian Queens, United States of America (USA)	1.000000	0.03
Cincinnati Cancer Center, United States of America (USA)	1.000000	0.03
The Valley Health System, United States of America (USA)	1.000000	0.03
Oklahoma Cancer Specialists and Research Institute (OCSRI), United States of America (USA)	1.000000	0.03
Jefferson Abington Hospital, United States of America (USA)	0.500000	0.02
Sidney Kimmel Cancer Center (SKCC), TJU, United States of America (USA)	0.500000	0.02

Interested in Medical Biotechnology?

Research leaders

2026 Research Leaders

The Nature Index 2026 Research Leaders reveal the leading institutions and countries/territories in the natural sciences, health sciences, applied sciences and social sciences, according to their output in Nature Index journals in 2025.

Access free

Latest supplement

Nature Index 2026 Nanoscience and nanotechnology

From programmable RNA architectures to next-generation materials for energy and healthcare, researchers are harnessing the unusual properties of the nanoscale to tackle some of society's biggest challenges. This supplement explores the discoveries that are driving the field, the hurdles that remain and the institutions that are leading in nanoscience and nanotechnology research.

Access free

Nature Index 2026 Chemistry

Chemistry research is undergoing a period of transformation, driven by new technologies and mounting environmental pressures. In this supplement, we explore the trends behind China’s extraordinary rise in chemistry output, and why efforts to curb the use of PFASs are accelerating worldwide. We also look at the innovations that could redefine how chemicals are designed, produced and recycled.

Access free

Research highlights of partners

Pre-empting a future pandemic

The University of Queensland (UQ)
26 Dec 2023
Overexcitable neurons lead to autistic-like behaviours in mice

Institute for Basic Science (IBS)
30 Nov 2023
How the brain wakes up after anaesthesia

Southern University of Science and Technology (SUSTech)
31 Oct 2023

Research highlights